Best adjuvant (assist) for chemotherapy | 1+1>487% |
Effectively improve chemotherapy effect, treatment, immunity.
Reduce side effects and recurrence.
Overview / Relation / Abstract / Role / Principle / Action / Mechanism / Function / Work |
Leukemia - Eosinophilic: Latest Research
Abstract / Summary / Overview of Apoptosis.
Why do cells undergo apoptosis?
The relationship between cancer cells and apoptosis.
Where are the weaknesses and symptoms of cancer cells?
Are cancer cells aggressive?
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work)
Solamargine's major function mechanism:
Solamargine vs cancer
Best Chemotherapy Adjuvant. (1+1>478%)
Effectively improve chemotherapy effect and cure.
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Extract : https://www.cancer.net/cancer-types/
Unknown Primary: Latest Research
You will read about the scientific research being done to learn more about this type of cancer and how to treat it.
Doctors are working to learn more about cancer of unknown primary (CUP), ways to prevent cancer, how to best treat CUP, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the best diagnostic and treatment options for you.
Using tumor genetics to diagnose the primary site. Different tissues within the body make different proteins, depending on which genes are active. This is called gene expression. For example, genes expressed by healthy lung cells are different than genes expressed by healthy colon cells. When cancer develops somewhere in the body, it usually has the same pattern of gene expression as the place where the cancer started. A tumor sample from a biopsy can be analyzed to figure out which genes are being expressed. This can usually predict where the cancer began.
As explained in the Types of Treatment section, site-treatment based on gene expression profiling prediction is being used instead of empiric chemotherapy as the standard treatment for people with CUP who do not fit into a specific subgroup. Ongoing clinical trials continue to look at the outcomes of site-specific treatment using gene expression profiling.
Targeted therapy. As explained in the Types of Treatment section, targeted therapy directs treatment at specific genes and proteins that are involved in the growth and survival of cancer cells. Learn more about the basics of targeted treatments.
Several targeted therapies are approved by the FDA for specific cancers. Examples include HER2 targeted therapy for HER2-positive breast cancer, BRAF inhibitors for BRAF-mutated melanoma, and EGFR inhibitors for EGFR-mutated non-small cell lung cancer. However, no targeted therapies are currently approved to treat CUP specifically, and the targeted drugs approved for other cancers have not been tested for CUP.
Since CUP covers many tumor types, it is likely that some of these cancers have molecular abnormalities that have been successfully targeted in other cancer types. Until recently, testing for potential molecular targets (such as HER2, BRAF, and EGFR) had not been performed in CUP. With the availability of comprehensive molecular profiling, recent studies have found that the incidence of potentially treatable molecular abnormalities (using targeted treatments already approved for other cancers) is approximately 25% in CUP.
The efficacy of targeted treatment aimed at these detected molecular abnormalities has not yet been adequately tested in patients with CUP. However, a few such patients treated outside of clinical trials (with clinically available drugs) have had excellent responses. In ongoing clinical trials, people with CUP whose tumors have specific molecular abnormalities are being treated with drugs targeted against that abnormality. These clinical trials provide a major opportunity to identify additional effective treatment options for specific patient groups.
- Immunotherapy. Immunotherapy helps the immune system fight cancer. During the last several years, many new immunotherapy drugs have been developed. For example, treatments that target PD-1 and PD-L1 pathways have become standard parts of treatment for several common cancers, including lung, kidney, bladder, head and neck, and certain breast and colon cancers.
Since people with CUP can have cancer that started in any of these locations, researchers think that some people with CUP could also benefit from immunotherapy. In addition to cancer type, several other predictors of responsiveness to immunotherapy have been identified, including high tumor PD-1 or PD-L1 expression, high microsatellite instability (MSI-H), or high tumor mutational burden (TMB) All of these abnormalities have been detected in CUP, and can be detected with comprehensive molecular profiling. Clinical trials are ongoing to understand the results of immunotherapy treatment in people with CUP. Learn more about the basics of immunotherapy.
New types of treatment. Many new drugs are being tested for the first time in studies called phase I clinical trials. Usually, these clinical trials are not specifically for CUP, but accept patients of all types of cancer who have already received all standard treatments. The goals of these studies are to identify the side effects and best doses for these new drugs, as well as to learn if they could be effective against cancer.
Palliative care/supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current cancer treatments to improve comfort and quality of life for patients.
Abstract / Summary / Overview of Apoptosis.
Overview of apoptosis
•Programmed cell death
•Apoptosis is a form of programmed cell death, or “cellular suicide.”
•Apoptosis is different from necrosis, in which cells die due to injury.
•Apoptosis removes cells during development, eliminates potentially cancerous and virus-infected cells, and maintains balance in the body.
Why do cells undergo apoptosis?
- Basically, apoptosis is a general and convenient way to remove cells that should no longer be part of the organism.
- Some cells are abnormal and could hurt the rest of the organism if they survive, such as cells with viral infections or DNA damage.
- Apoptosis is part of development
- In many organisms, programmed cell death is a normal part of development.
The relationship between cancer cells and apoptosis
Apoptosis can eliminate infected or cancerous cells.
When a cell’s DNA is damaged, it will typically detect the damage and try to repair it.
If the damage is beyond repair, the cell will normally send itself into apoptosis, ensuring that it will not pass on its damaged DNA.
When cells have DNA damage but fail to undergo apoptosis, they may be on the road to cancer.
However, “successful” cancer cells successfully evade the process of apoptosis.
This allows them to divide out of control and accumulate mutations (changes in their DNA).
Apoptosis is key to immune function
Apoptosis also plays an essential role in the development and maintenance of a healthy immune system.
Where are the weaknesses and symptoms of cancer cells?
The symptoms of cancer cells are in the nucleus.
The nucleus controls the outer cytoplasm, cell composition, cell viability, etc.
DNA mutations also mutate in the nucleus.
Therefore, to treat cancer cells, we must first enter the nucleus.
Let the “regulatory cell gene” mechanism enter the nucleus to regulate
Are cancer cells aggressive?
After the action of Solamargine, the aggressiveness of cancer cells is alleviated.
So after using Solamargine, many patients feel that I am half better.
Although the tumor does not disappear quickly, patients feel that the degree of aggressiveness is reduced.
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work).
Solamargine's major function mechanism:
When Solamargine enter,
Solamargine activates receptors that are turned off by cancer cells, allowing cancer cells to modulate again.
Solamargine modulates the anti-modulates genes of cancer cells, making cancer cells less resistant.
Reduced drug resistance
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Solamargine modulates the mutated genes in cancer cells and then initiates cancer cell apoptosis to achieve anti-cancer effects.
Solamargine combined with which chemotherapy drugs are more effective in treating cancer cells?
Solamargine vs cancer
Solamargine vs cancer
The picture shows the death of cancer cells.
The black and black parts are cancer cell nuclei.
Even if the nucleus ruptures, the cancer cells will die.
The figure shows that cancer cells can cause death.
The figure shows that cancer cells can cause death.
The figure shows that the death of lung cancer cells is relatively slow, and it will not be obvious until eight hours later.
The figure shows that the death of liver cancer cells is very obvious, even more obvious in eight hours.
The graph shows that breast cancer cells die faster. It was obvious from the beginning that breast cancer is easy to treat, and patients with breast cancer need not worry.
Best Chemotherapy Adjuvant. (1+1>487%)
Effectively improve chemotherapy effect and treatment.
ANTI-CANCER
Patent protection in 32 nations.
A comparison study showing Solamargine vs. other therapeutic drugs with respect to lung cancer cells.
A comparison study showing Solamargine vs. other chemotherapeutic drugs with respect to breast cancer cells.
SR-T100 combination therapy with effective result against breast cancer cells.
Combination Therapy | Research results for lung cancer cells.
A. Chemotherapy (100μM), 16% of cancer cell apoptosis.
B. Alone SM (4.8μM), 28% of cancer cell apoptosis.
C. SM (4.80μM) + Chemotherapy (40μM), 66% of cancer cells apoptosis.
D. SM (4.80μM) + Chemotherapy (100μM), 78% of cancer cell apoptosis.
SM has a clearing effect better than Chemotherapy.
The combined treatment of Solamargine and Chemotherapy significantly increased the apoptosis of lung cancer cells.
SM (4.8μM) + Chemotherapy (40μM), increased from 16% to 66% (up to 4.125 times).
SM (4.8μM) + Chemotherapy (100μM), increased from 16% to 78% (up to 4.875 times).
Reorganized from: BBRC. Action of Solamargine on TNFs and drug-resistant human lung cancer cells 2004.
The best solution for cancer cells.